Putnam Investments LLC Decreased Its Jazz Pharmaceuticals Plc (JAZZ) Holding as Stock Price Rose

January 23, 2018 - By Lynda A. Deweese

Investors sentiment decreased to 1.03 in 2017 Q3. Its down 0.36, from 1.39 in 2017Q2. It is negative, as 39 investors sold JAZZ shares while 82 reduced holdings. 31 funds opened positions while 94 raised stakes. 53.58 million shares or 3.54% more from 51.74 million shares in 2017Q2 were reported. Point72 Asset Mgmt LP holds 74,700 shares or 0.05% of its portfolio. Enterprise Financial Svcs Corp reported 0.01% stake. Schroder Investment Management has 354,900 shares. Bancorpsouth has 3,273 shares for 0.05% of their portfolio. Acadian Asset Management Lc has 0% invested in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) for 48 shares. Viking Investors LP stated it has 1.13% of its portfolio in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Neuberger Berman Group Ltd Liability Company has 0.02% invested in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Prelude Cap Management Ltd Liability Com holds 0.4% or 30,312 shares. Orbimed Advisors Ltd Liability Corporation owns 749,200 shares. Ajo LP stated it has 5,969 shares. Fjarde Ap has 0.05% invested in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Polar Llp reported 361,018 shares. Tdam Usa holds 4,879 shares or 0.04% of its portfolio. Ardsley Advisory Prtn, a Connecticut-based fund reported 77,000 shares. Howe & Rusling Incorporated, New York-based fund reported 600 shares.

Since August 10, 2017, it had 0 insider purchases, and 19 sales for $3.38 million activity. O’Keefe Kenneth W sold $94,248 worth of stock. Treacy Paul sold $186,884 worth of stock. Another trade for 662 shares valued at $94,248 was sold by ENRIGHT PATRICK G. 200 shares were sold by MILLER MICHAEL PATRICK, worth $28,876 on Tuesday, August 15. The insider COZADD BRUCE C sold 3,000 shares worth $450,000. Shares for $102,078 were sold by Gray Peter on Thursday, August 10.

Putnam Investments Llc decreased its stake in Jazz Pharmaceuticals Plc (JAZZ) by 0.27% based on its latest 2017Q3 regulatory filing with the SEC. Putnam Investments Llc sold 22,316 shares as the company’s stock rose 8.72% with the market. The institutional investor held 8.28M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $1.21B, down from 8.30M at the end of the previous reported quarter. Putnam Investments Llc who had been investing in Jazz Pharmaceuticals Plc for a number of months, seems to be less bullish one the $9.14B market cap company. The stock increased 2.50% or $3.72 during the last trading session, reaching $152.42. About 508,612 shares traded or 4.23% up from the average. Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) has risen 1.25% since January 23, 2017 and is uptrending. It has underperformed by 15.45% the S&P500.

Putnam Investments Llc, which manages about $89.35B and $43.31 billion US Long portfolio, upped its stake in Oracle Corp (NYSE:ORCL) by 102,116 shares to 711,759 shares, valued at $34.41M in 2017Q3, according to the filing. It also increased its holding in A by 96,901 shares in the quarter, for a total of 877,345 shares, and has risen its stake in Paypal Holdings Inc.

Analysts await Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) to report earnings on February, 27. They expect $2.63 EPS, up 37.70 % or $0.72 from last year’s $1.91 per share. JAZZ’s profit will be $157.68M for 14.49 P/E if the $2.63 EPS becomes a reality. After $2.93 actual EPS reported by Jazz Pharmaceuticals Public Limited Company for the previous quarter, Wall Street now forecasts -10.24 % negative EPS growth.

More notable recent Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) news were published by: Seekingalpha.com which released: “Jazz Pharmaceuticals Plc (JAZZ) Q3 2017 Results – Earnings Call Transcript” on November 08, 2017, also Prnewswire.com with their article: “Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz …” published on May 31, 2016, Prnewswire.com published: “Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results” on February 28, 2017. More interesting news about Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) were released by: Benzinga.com and their article: “Martin Shkreli Thinks Jazz Pharmaceuticals Could Be Worth $20 Billion, While …” published on September 12, 2016 as well as Prnewswire.com‘s news article titled: “Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz …” with publication date: September 19, 2011.

Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) Ratings Coverage

Among 21 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Jazz Pharmaceuticals has $229 highest and $124 lowest target. $179.76’s average target is 17.94% above currents $152.42 stock price. Jazz Pharmaceuticals had 70 analyst reports since August 3, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Buy” rating in Sunday, December 10 report. Janney Capital initiated the shares of JAZZ in report on Thursday, August 25 with “Neutral” rating. The firm has “Neutral” rating by H.C. Wainwright given on Friday, November 10. The stock of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) earned “Outperform” rating by BMO Capital Markets on Wednesday, June 29. On Tuesday, January 2 the stock rating was maintained by Stifel Nicolaus with “Buy”. Mizuho maintained Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) on Friday, October 13 with “Hold” rating. The stock has “Hold” rating by H.C. Wainwright on Friday, August 25. The rating was maintained by RBC Capital Markets with “Buy” on Tuesday, June 27. Deutsche Bank maintained the shares of JAZZ in report on Monday, July 17 with “Buy” rating. The rating was initiated by Bernstein on Wednesday, November 25 with “Market Perform”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.